• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Medical Device Market
    Medical Device News
    Medical Device Stocks
    • Medical Device Market
    • Medical Device News
    • Medical Device Stocks
    medical-device-investing

    HTG Molecular Diagnostics Announces Completion of Public Offering of Common Stock

    Gabrielle Lakusta
    Jan. 24, 2018 08:59AM PST
    Medical Device Investing

    HTG Molecular Diagnostics (NASDAQ:HTGM) a provider of instruments, reagents and services for molecular profiling applications, today announced the completion of its previously announced underwritten public offering of 13,915,000 shares of its common stock at a price to the public of $2.90 per share, including 1,815,000 shares sold pursuant to the exercise in full of the …

    HTG Molecular Diagnostics (NASDAQ:HTGM) a provider of instruments, reagents and services for molecular profiling applications, today announced the completion of its previously announced underwritten public offering of 13,915,000 shares of its common stock at a price to the public of $2.90 per share, including 1,815,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.
    As quoted in the press release:

    All of the shares in the offering were sold by HTG. The aggregate gross proceeds from the offering are approximately $40.4 million, before deducting the underwriting discounts and commissions and offering expenses.

    Leerink Partners LLC and Cantor Fitzgerald & Co. acted as joint book-running managers for the offering. H.C. Wainwright & Co., LLC and LifeSci Capital LLC acted as co-managers for the offering.

    Click here to read the full press release.

    cantor-fitzgeraldunderwritten-public-offeringpublic-offeringhtg-molecular-diagnosticsmolecular-diagnosticsmedical-device-investing
    The Conversation (0)

    Go Deeper

    AI Powered
    A floating DNA double helix above a hand with a blue background.

    Top 4 NASDAQ Genetics Stocks (Updated January 2026)

    TSXV:DGTL

    DGTL Holdings

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Medical Device Investing Stocks

    Cardiex Limited

    Cardiex Limited (CDX:AU)
    CDX:AU

    Cleo Diagnostics

    Cleo Diagnostics (COV:AU)
    COV:AU

    Applied UV

    Applied UV (AUVI:NSD)
    AUVI:NSD

    Avricore Health

    Avricore Health (AVCR:CC)
    AVCR:CC
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES